Oxford BioDynamics has developed a proprietary diagnostic technology platform EpiSwitch™ for the reliable, sensitive, specific and early detection of aberrant gene expression.
The EpiSwitch™ technology offers a highly affordable means of non-invasive screening, early detection, monitoring and prognosis of major diseases associated with aberrant gene expression including cancer, inflammatory, cardiovascular, and neurodegenerative conditions.
The technology provides the early detection of aberrant gene expression in very low copy numbers and in a small sample of abnormal cells, equivalent to ”finding a needle in a haystack” at the early stage of the disease.
The EpiSwitch™ test is non invasive and produces results in less than four hours.
